AstraZeneca’s experimental COPD drug tozorakimab reduced moderate and severe exacerbations by as much as 34% in two Phase III ...
A global coalition of patient advocates, industry and non-profit organisations has called on governments to strengthen action on chronic obstructive pulmonary ...
Background Pulmonary rehabilitation (PR) is the cornerstone of non-pharmacological treatment for chronic obstructive pulmonary disease (COPD), yet fatigue often persists despite rehabilitation. We ...
Macrolide therapy is an established and effective treatment for selected patients with chronic obstructive airways diseases who experience frequent exacerbations despite optimal therapy. Randomised ...
On 8, 2026, CNBC reported that AstraZeneca PLC (NYSE:AZN) released full results from two successful late-stage trials of tozorakimab, an experimental drug for chronic obstructive pulmonary ...
Biofilms are complex microbial communities that adhere to a surface and encase themselves in a viscous matrix they produce.
Researchers developed sex-specific models using CT imaging and compared their efficacy in predicting the incidence and prevalence of COPD.
New models for asthma, atopic dermatitis and chronic obstructive pulmonary disease (COPD) expand GeneAI Forecast to 18 ...
We work in healthcare and are well educated in symptoms and diagnoses. But with some symptoms, we don't realize what's really happening.
Researchers conducted a cohort study to compare lung cancer risk among patients with COPD and T2DM using SGLT2 inhibitors vs sulfonylureas.
Some believe that laughter is the best remedy for getting rid of worries, but a new study conducted in Turkey has shown that laughter is also the best treatment for chronic obstructive pulmonary ...
Congress 2026, AstraZeneca presented the design of the Phase IIb PRESTO trial, a large study set to evaluate whether AZD6793, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results